

VCBeat Health Contact Us

China Healthcare Select

Vertical Industries 

Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory

Home CHANGCHUN HIGH-TECH Subsidiary GenSci145 Tablet Receives FDA Approval for Clinical Trial IND

CHANGCHUN HIGH-TECH Subsidiary GenSci145 Tablet Receives FDA Approval for Clinical Trial IND

Jun 01, 2026 17:37 CST Updated Jun 04, 15:52

Share:

CHANGCHUN HIGH-TECH

Pharmaceutical R&D Developer

vcbeatglobal@vcbeat.net 

SERVICES

Partnership Development Market Entry Advisory Ecosystem Engagement Advisory

COMPANY

About VCBeat Why VCBeat Contact Us

CHANNELS

China Healthcare Select Insights MNC China Lens Events VB100 GMPC

MORE

PRIVACY VCBEAT CHINA

© 2025 VCBeat. All rights reserved.